EP Patent

EP1863481A1 — Methods for administering ixabepilone

Assigned to Bristol Myers Squibb Co · Expires 2007-12-12 · 18y expired

What this patent protects

Methods for administering ixabepilone to patients are provided, wherein ixabepilone has the formula (I). One aspect of the invention comprises the use of a Y-site or dual source administration technique that provides enhanced ixabepilone stability and allows for greater flexibili…

USPTO Abstract

Methods for administering ixabepilone to patients are provided, wherein ixabepilone has the formula (I). One aspect of the invention comprises the use of a Y-site or dual source administration technique that provides enhanced ixabepilone stability and allows for greater flexibility in infusion time and/or product preparation.

Drugs covered by this patent

bendamustine-hydrochloride (BENDAMUSTINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP1863481A1
Jurisdiction: EP
Classification: —
Expires: 2007-12-12
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.